Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ordopidine
- Development stage
- Phase 1
- Lead developer
- Prilenia
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ordopidine (ACR325) is a small molecule dopaminergic stabilizer developed primarily for the treatment of Parkinson’s disease and psychoses, including bipolar disorder. It acts by increasing dopamine and noradrenaline levels in the forebrain while inhibiting excessive dopamine activity in other brain regions without causing unwanted motor side effects. Ordopidine has demonstrated promising results in preclinical models for both motor function and psychosis. Its mechanism involves low-affinity antagonism at dopamine D2 receptors[1][3][6].
- Other names
- ordopidine1-ethyl-4-(2-fluoro-3-(methylsulfonyl)phenyl)piperidine871351-60-9UNII-0P43SIA7J6UNII0P43SIA7J6UNII 0P43SIA7J6
02
Targets
DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)
Beyond the preview
Go deeper on ordopidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ordopidine.